Aurothiomalate (disodium)

Aurothiomalate (disodium) is a TRPA1 inhibitor. Aurothiomalate (disodium) inhibits NF-κB activation and iNOS expression. Aurothiomalate (disodium) promotes M2 transformation of macrophages and increases the expression of TREM-2 and arginase-1. Aurothiomalate (disodium) can be used in the study of liver fibrosis/cirrhosis and arthritis[1][2].

Product Specifications

CAS Number

[74916-57-7]

UNSPSC

12352211

Target

Arginase; NF-κB; NO Synthase; TREM receptor; TRP Channel

Related Pathways

Immunology/Inflammation; Membrane Transporter/Ion Channel; Metabolic Enzyme/Protease; Neuronal Signaling; NF-κB

Applications

Metabolism-protein/nucleotide metabolism

Field of Research

Metabolic Disease; Inflammation/Immunology

Smiles

O=C(CC(C([O-])=O)[S-])[O-].[Na+].[Au+].[Na+]

Molecular Formula

C4H3AuNa2O4S

Molecular Weight

390.08

References & Citations

[1]Nummenmaa E, et al. TRPA1 expression is downregulated by dexamethasone and aurothiomalate in human chondrocytes: TRPA1 as a novel factor and drug target in arthritis. RMD Open. 2017 Sep 4;3 (2) :e000556.|[2]강건욱, et al. Pharmaceutical composition, comprising gold compound, for preventing or treating liver fibrosis or liver cirrhosis. WO2016028092A2. 서울대학교 산학협력단. 2015-08-19.